Show simple item record Mucci, Armida Vignapiano, Annarita Bitter, István Austin, Stephen F Delouche, Camille Dollfus, Sonia Erfurth, Andreas Fleischhacker, W Wolfgang Giordano, Giulia M Gladyshev, Igor Glenthøj, Birte Gütter, Karoline Hofer, Alex Hubeňák, Jan Kaiser, Stefan Libiger, Jan Melle, Ingrid Nielsen, Mette Ø Papsuev, Oleg Rybakowski, Janusz K Sachs, Gabriele Üçok, Alp Wojciak, Pawel Galderisi, Silvana 2021-06-08T07:56:06Z 2021-06-08T07:56:06Z 2019
dc.identifier.citation journalVolume=29;journalIssueNumber=8;journalTitle=EUROPEAN NEUROPSYCHOPHARMACOLOGY;pagerange=947-959;journalAbbreviatedTitle=EUR NEUROPSYCHOPHARM;
dc.identifier.uri doi:10.1016/j.euroneuro.2019.05.006
dc.description.abstract Negative symptoms represent an unmet need of treatment in schizophrenia. Although a consensus exists on negative symptom construct, and second generation assessment instruments reflecting the consensus are available, studies still rely upon old assessment instruments, that do not reflect recent conceptualizations and might limit progress in the search for effective treatments. This is often the case in the European context, where one of the challenges encountered in designing large studies is the availability of validated instruments in the many languages of the continent. To address this challenge and promote sound research on negative symptoms in Europe, the ECNP Schizophrenia Network coordinated a large multicenter, multinational validation study of the Brief Negative Symptom Scale (BNSS). Clinically-stable subjects with schizophrenia (SCZ, N = 249) were recruited from 10 European Countries. Apart from BNSS, subjects were administered the Positive and Negative Syndrome Scale (PANSS) and standardized instruments for depression, extrapyramidal symptoms and psychosocial functioning. Results showed an excellent internal consistency, convergent and discriminant validity of BNSS and replicated a 5 factor-model. A larger number of subjects with predominant negative symptoms, i.e. the target population for clinical trials, was identified by using the BNSS compared to the PANSS. Regression analysis showed that BNSS-avolition, a key negative symptom poorly assessed by PANSS, explained 23.9% of psychosocial functioning, while no combination of the PANSS core negative symptoms showed the same impact on functioning. The study demonstrated that BNSS has substantial advantages with respect to PANSS for the identification of the avolition domain and subjects with predominant negative symptoms.
dc.relation.ispartof urn:issn:0924-977X
dc.title A large European, multicenter, multinational validation study of the Brief Negative Symptom Scale
dc.type Journal Article 2019-08-02T08:16:26Z
dc.language.rfc3066 en
dc.rights.holder NULL
dc.identifier.mtmt 30747432
dc.identifier.pubmed 31255394
dc.contributor.department SE/AOK/K/Pszichiátriai és Pszichoterápiás Klinika
dc.contributor.institution Semmelweis Egyetem

Files in this item

This file is available only from Semmelweis network


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account